Anatara Lifesciences Ltd (ASX:ANR)

Australia · Delayed Price · Currency is AUD

0.0100

0.00 (0.00%)

Jul 16, 2026, 12:36 PM AEST

42.86% (1Y)

Market Cap	3.16M +111.5%
Revenue (ttm)	623.76K -30.3%
Net Income	-1.31M
EPS	-0.01
Shares Out	315.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,436
Open	0.0100
Previous Close	0.0100
Day's Range	0.0100 - 0.0100
52-Week Range	0.0050 - 0.0200
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Anatara Lifesciences

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company’s products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight redu... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol ANR

Full Company Profile

Financial Performance

In fiscal year 2025, Anatara Lifesciences's revenue was 969,456, an increase of 50.53% compared to the previous year's 644,026. Losses were -1.95 million, 34.7% more than in 2024.

Financial Statements